Yahong Pharmaceutical (688176.SH): Data related to the APL-1702 international multi-center phase III clinical trial were published in the international journal “Med”

Zhitong Finance App News, Yahong Pharmaceutical (688176.SH) issued an announcement. Recently, the results of a prospective, randomized, double-blind, placebo-controlled international multi-center phase III clinical trial for the treatment of high-grade squamous intraepithelial lesion (HSIL), the company's product APL-1702 have been published online by Cell Press's “Med”. “Med” was founded by Cell Press. It is the flagship medical journal launched by Cell Press after “Cell” and “Chem,” and is a top journal in Journal Citation Reports (JCR) Q1 and the Shuangyi District of the Chinese Academy of Sciences.

APL-1702 is a photodynamic therapy product integrating medicine and equipment. As a topical non-surgical treatment, it is used to treat high-grade squamous intraepithelial lesion (HSIL) of the cervix (High-Grade Squamous Intraepithelial Lesion, HSIL). This product consists of APL-1702 ointment and device. Currently, the above products are still in the review and approval stage of the Drug Evaluation Center of the State Drug Administration. There is uncertainty about whether the above products can be successfully marketed and when they will be marketed, and there is also some uncertainty about whether the products can finally achieve their commercial goals after approval. The publication of clinical trial data will not have a significant impact on the company's recent performance.